MD Anderson study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018

Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). They believe two existing therapies may hold promise for clinical studies for this deadly and common lung cancer for which relapse often occurs within one year following treatment.

The study revealed a unique "addiction" between the enzyme protein kinase C delta (PKCδ) found in NSCLC tumors and standard-of-care treatment called EGFR tyrosine kinase inhibitors (TKIs). Based on mouse and human tissue samples, this link allows PKCδ to lessen TKIs' ability to forestall cancer. Findings were published in the Dec. 10 online issue of Cancer Cell.

Approximately 160,000 people in the U.S. are diagnosed with NSCLC each year, and roughly 15,000 have metastatic disease with EGFR mutations.

"Multiple methods of resistance to EGFR TKIs have been identified in EGFR-mutant non-small cell lung cancer, but resistance to treatment remains a major challenge," said Mien-Chie Hung, Ph.D., chair of Molecular and Cellular Oncology. "Our study identified PKCδ as a common mediator shared by multiple methods of resistance to EGFR TKIs, and it significantly demonstrates inhibition of PKCδ facilitates EGFR TKIs to induce regression of resistant tumors with EGFR mutation."

EGFR are proteins belonging to a family called receptor tyrosine kinases (RTKs) frequently mutated in NSCLC which cause cellular changes, including enhanced cell growth, tumor formation and metastasis. TKIs interrupt EGFR cell signaling and suppress tumor development. Yet treated tumors eventually develop resistance due to multiple mechanisms known collectively as tumor heterogeneity resistance, which includes additional mutations of EGFR and/or overexpression of other RTKs.

New generations of TKIs targeting specific resistant mechanisms have been developed, which help patients live for several more months, but relapse still occurs and patients eventually are left with no treatment options. To overcome tumor heterogeneity resistance, it is critical to identify a common mediator, which, when blocked, may provide effective treatment, Hung added.

The team observed high levels of PKCδ activation in tumor-bearing mice and patient tissue samples, which revealed PKCδ is a requirement for TKI resistance and is associated with worse progression-free survival following TKI treatment.

The team discovered a combination of two therapies studied in mice, gefitinib and sotrastaurin, appear to be effective as a potential therapy strategy for EGFR-mutant NSCLC TKI resistance. Gefitinib is an FDA-approved TKI for EGFR-mutant NSCLC, while sotrastaurin is approved for use in clinical trials in cancer and other diseases.

"Since gefitinib has received regulatory approval in NSCLC patients and sotrastaurin is available for clinical studies, the combination could be readily tested in clinical trials, especially for patients whose tumor has developed TKI resistance," said Hung. "It is our hope that new therapies that could result from such studies may be of benefit to patients who have not responded to existing treatments."
MD Anderson team members included Pei-Chih Lee, Ph.D.; Yueh-Fu Feng, M.D.; Hirohito Yamaguchi, D.V.M., Ph.D.; Wei-Jan Wang, Ph.D.; Xuan Hong, M.D., Ph.D.; Baozhen Ke, B.S.; Weiha Xia, M.D.; Yongkun Wi, M.D., Ph.D.; Zhengyu Zha, Ph.D.; Yan Wang, Ph.D.; Lei Nie, Ph.D.; Junwei Hou, Ph.D.; Chun-Te Chen, Ph.D.; Longfei Huo, Ph.D.; Wen-Hao Yang, Ph.D.; Rong Deng, Ph.D.; Katusuya Nakai, M.D.; Yi-Hsin Hsu, Ph.D.; Shi-Shin Chang, Ph.D.; Tai-Jan Chiu, M.D.; Jun Tang, M.D. and Jennifer Hsu, Ph.D., all of the Department of Molecular and Cellular Oncology; Ran Zhang, Ph.D., Li Wang, Ph.D., and Bingliang Fang, M.D., Ph.D., of Thoracic and Cardiovascular Surgery.

Other participating institutions include: Chang Gung Memorial Hospital, Saint Paul's Hospital, and Chang Gung University College of Medicine, Taoyuan, Taiwan; Harbin Medical University Cancer Hospital, Heilongjiang, China; China Medical University and National Chung-Hsing University, Taichung, Taiwan; Sun Yat-sen University, Guangzhou, China; Chang Gung University College of Medicine, Kaohsiung, Taiwan; Langone Medical Center, New York; and Dana-Farber Cancer Institute, Boston.

The study was funded by the National Institutes of Health (CA109311, CA099031 and P30 CA16672); The MD Anderson Cancer Center-China Medical University and Hospital Sister Institution Fund; the Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE, MOST 105-2911-I-002-302); the Ministry of Health and Welfare; China Medical University Hospital Cancer Research Center of Excellence (MOHW106-TDU-B-212-144003); the Center for Biological Pathways; and Chang Gung Memorial Hospital Grant (CMRPG3D1911).

University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to